Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus

The incidence of renal‐related adverse events (AEs) with canagliflozin in patients with type 2 diabetes mellitus from a pooled population of patients in 7 active‐ and placebo‐controlled trials (N = 5598) and in a 104‐week study vs glimepiride (N = 1450) was low and similar in canagliflozin and non‐c...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Mehul, Yavin, Yshai, Balis, Dainius, Sun, Don, Xie, John, Canovatchel, William, Rosenthal, Norm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485046/
https://www.ncbi.nlm.nih.gov/pubmed/28083972
http://dx.doi.org/10.1111/dom.12876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485046/
https://www.ncbi.nlm.nih.gov/pubmed/28083972
http://dx.doi.org/10.1111/dom.12876

Ejemplares similares